Home » Topics » Regulatory

Regulatory
RSS

The antiplatelet agent triflusal now shown to inhibit NF-kappaB activation

Jan. 10, 2000

Olanzapine and fluoxetine in combination useful for refractory depression

Jan. 10, 2000

Miltefosine tested as oral treatment for leishmaniasis

Jan. 4, 2000

CFC-free flunisolide to be developed by 3M/Forest partnership

Jan. 3, 2000

NDA filed for intranasal scopolamine during fourth quarter

Jan. 3, 2000

FDA approves Ligand's Targretin Capsules for treatment of CTCL

Dec. 30, 1999

AstraZeneca seeks approval of Atacand HCT in the U.S.

Dec. 30, 1999

Reboxetine + pindolol rapidly relieves symptoms of depression and other CNS disorders

Dec. 30, 1999

Injectable levocarnitine approved for use in dialysis in U.S.

Dec. 28, 1999

FDA clears Taxotere for marketing in NSCLC

Dec. 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...